Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and HAAG +/- HMA in Relapsed/Refractory AML
NCT05805072Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of selinexor in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Number of Participants With Complete Remission (CR) or Complete Remission with Incomplete Hematologic Recovery (CRi). Status: unknown.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05805072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805072.